Name
ORAL ABSTRACT: Extended follow-up of KEYNOTE-B61: First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinoma (nccRCC)
Date & Time
Friday, April 19, 2024, 12:49 PM - 12:59 PM
Speakers
Martin Voss, MSKCC
Martin Voss
Description

Martin Voss, MD, Memorial Sloan Kettering Cancer Center

Presentation Slides

Location Name
Auditorium
Full Address
Melia Sitges Hotel
Calle Joan Salvat Papasseit 38
Sitges Spain 08870
Spain